Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Recommendation of “Hold” from Analysts

Posted by Paula Ricardo on Feb 7th, 2026

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH – Get Free Report) have received an average rating of “Hold” from the seven research firms that are currently covering the stock, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $80.60.

A number of brokerages have weighed in on PBH. Oppenheimer reduced their price target on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a report on Tuesday, October 21st. Canaccord Genuity Group reduced their target price on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th. Jefferies Financial Group cut their price target on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a report on Friday, January 30th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Thursday, January 22nd.

Get Our Latest Research Report on Prestige Consumer Healthcare

Insider Transactions at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 719 shares of the stock in a transaction on Friday, November 28th. The shares were sold at an average price of $60.00, for a total value of $43,140.00. Following the completion of the transaction, the vice president owned 42,329 shares in the company, valued at approximately $2,539,740. This represents a 1.67% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several large investors have recently modified their holdings of PBH. AQR Capital Management LLC boosted its stake in Prestige Consumer Healthcare by 11.9% in the 1st quarter. AQR Capital Management LLC now owns 30,056 shares of the company’s stock valued at $2,558,000 after buying an additional 3,200 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Prestige Consumer Healthcare by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company’s stock valued at $2,535,000 after acquiring an additional 1,289 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Prestige Consumer Healthcare by 28.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock valued at $46,997,000 after purchasing an additional 120,965 shares in the last quarter. Jane Street Group LLC boosted its stake in shares of Prestige Consumer Healthcare by 204.0% in the 1st quarter. Jane Street Group LLC now owns 104,802 shares of the company’s stock valued at $9,010,000 after purchasing an additional 70,330 shares in the last quarter. Finally, Geneos Wealth Management Inc. grew its holdings in shares of Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after purchasing an additional 269 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH opened at $66.48 on Friday. The company has a market cap of $3.20 billion, a price-to-earnings ratio of 17.59, a PEG ratio of 2.06 and a beta of 0.43. The business has a 50 day moving average price of $63.19 and a 200 day moving average price of $64.06. The company has a quick ratio of 2.51, a current ratio of 3.11 and a debt-to-equity ratio of 0.58. Prestige Consumer Healthcare has a twelve month low of $57.25 and a twelve month high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last issued its quarterly earnings results on Thursday, February 5th. The company reported $1.14 EPS for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The business had revenue of $283.44 million for the quarter, compared to analyst estimates of $286.93 million. During the same quarter last year, the firm earned $1.22 earnings per share. The firm’s quarterly revenue was down 2.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. Research analysts predict that Prestige Consumer Healthcare will post 4.5 earnings per share for the current year.

Trending Headlines about Prestige Consumer Healthcare

Here are the key news stories impacting Prestige Consumer Healthcare this week:

Positive Sentiment: Management highlighted progress restoring Clear Eyes supply and said availability is improving, which supports a rebound in that brand’s sales going forward. Prestige Consumer Healthcare narrows fiscal 2026 revenue outlook to $1.1B while advancing Clear Eyes supply recovery
Positive Sentiment: The company narrowed and finalized its fiscal‑2026 revenue outlook to about $1.1 billion, which reduces uncertainty around full‑year expectations and may reassure investors. Prestige Consumer Healthcare Q3 revenue tops estimates, narrows guidance
Neutral Sentiment: Management posted the full slide deck and call transcript; these provide detail on segment trends, margins and working‑capital dynamics for investors doing deeper diligence. Q3 2026 Earnings Call Transcript
Negative Sentiment: Q3 results showed a small EPS miss: $1.14 reported vs. ~$1.16 consensus, and revenue of ~$283.4M was down roughly 2.4% year‑over‑year—factors that are short‑term headwinds for the stock. Prestige Consumer Healthcare (PBH) Q3 Earnings Lag Estimates
Negative Sentiment: Fiscal‑2026 EPS guidance was set at 4.54 (company’s figure), essentially flat-to-slightly below some sell‑side consensus (~4.55), leaving limited upside in near‑term estimates. Press release: Third Quarter and Year-to-Date Fiscal 2026 Results

About Prestige Consumer Healthcare

(Get Free Report)

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).